Plus Therapeutics Market capitalization 2024

The Plus Therapeutics Market capitalization history

YEAR	REVENUE (undefined USD)	GROSS MARGIN (%)	NET INCOME (undefined USD)
2029e	171.96	2,49	14.88
2028e	68.22	6,27	0.49
2027e	31.71	13,50	-6.51
2026e	-	-	-15.41
2025e	4.39	97,58	-13.39
2024e	5.17	82,80	-12.11
2023	4.91	87,12	-13.32
2022	0.22	1945,45	-20.28
2021	-	-	-13.4
2020	0.3	1426,67	-8.24
2019	7	61,14	-11.44
2018	6.65	64,36	-15.12
2017	6.41	60,37	-26.66
2016	11.38	76,19	-22.05
2015	11.66	72,64	-19.41
2014	7.6	61,32	-38.54
2013	12.2	71,97	-26.18
2012	14.5	72,41	-32.28
2011	10	61,60	-32.45
2010	10.63	63,22	-27.49
2009	14.73	76,99	-23.22
2008	6.85	72,99	-30.04
2007	6.05	93,06	-28.67
2006	7.93	79,45	-25.45
2005	6.01	47,42	-26.54
2004	6.82	50,29	-2.09

Plus Therapeutics Aktienanalyse

What does Plus Therapeutics do?

Plus Therapeutics Inc is a US pharmaceutical company specializing in the development and marketing of novel targeted cancer therapies. The company was founded in 2002 under the name Cygnus Biosciences Inc and changed its name to Plus Therapeutics Inc in 2018. Since then, the company has been listed on NASDAQ under the ticker symbol "PSTV". The history of the company dates back to 1998 when scientist James R. Baker Jr. founded Cygnus Biosciences to advance his cancer medicine research. Baker is considered one of the leading experts in the field of nanotechnology cancer research and has made a number of groundbreaking discoveries in this field. The business model of Plus Therapeutics is based on the development and marketing of novel cancer drugs, particularly those based on nanotechnology. The company aims to improve the effectiveness and safety of cancer drugs and thus contribute to improving the quality of life of cancer patients. Plus Therapeutics is divided into several divisions, including nanomedicine, biotechnology, and pharmaceuticals. In the field of nanomedicine, the company develops products based on targeted drug release. The goal is to transport the active ingredients in such a way that they specifically reach the site of the tumor and can have their full effect there. In the field of biotechnology, the company is developing new technologies to further improve the effectiveness and safety of cancer drugs. In the field of pharmaceuticals, Plus Therapeutics focuses on the development of cancer drugs based on nanotechnology. An important milestone in the history of Plus Therapeutics was the development of the drug DocePLUS, which is based on nanotechnology and can be used against breast cancer. DocePLUS has been approved by the FDA and is currently being tested in clinical trials. The company is also working on the development of other cancer drugs, including those that can be used against other types of cancer. Plus Therapeutics has an experienced management team and works closely with leading experts in the field of cancer medicine. The company has formed a number of partnerships and collaborations with other pharmaceutical companies and research institutions in the US and worldwide to advance its research and development. Overall, Plus Therapeutics aims to revolutionize cancer treatment and help cancer patients achieve a higher quality of life. With its innovative research and the goal of developing new targeted and more effective therapies, the company is on track to achieve this goal. Plus Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Plus Therapeutics's Market Capitalization

Plus Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Plus Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Plus Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Plus Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Plus Therapeutics Stock

What is the current Plus Therapeutics market capitalization?

The current market capitalization of Plus Therapeutics is 6.28 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Plus Therapeutics.

How has the market capitalization of Plus Therapeutics developed in recent years?

The market capitalization of Plus Therapeutics has increased/decreased by -5.86% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Plus Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Plus Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Plus Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Plus Therapeutics pay?

Over the past 12 months, Plus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Plus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Plus Therapeutics?

The current dividend yield of Plus Therapeutics is .

When does Plus Therapeutics pay dividends?

Plus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Plus Therapeutics?

Plus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Plus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Plus Therapeutics located?

Plus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Plus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Plus Therapeutics from 6/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/18/2024.

When did Plus Therapeutics pay the last dividend?

The last dividend was paid out on 6/18/2024.

What was the dividend of Plus Therapeutics in the year 2023?

In the year 2023, Plus Therapeutics distributed 0 USD as dividends.

In which currency does Plus Therapeutics pay out the dividend?

The dividends of Plus Therapeutics are distributed in USD.